A GLP-1 receptor agonist derived from Gila monster venom (exendin-4). Structurally it is GLP-1 receptor agonist (exendin-4, 39 aa).

How strong is the evidence for Exenatide?

PeptideHormone grades Exenatide at the "Established" evidence tier — its mechanism and core effects are settled across the peer-reviewed literature. It is catalogued as an engineered analog built on an endogenous hormone, and the tier is an editorial judgment about the public literature that can change as the science does.

What is the half-life of Exenatide?

The reported circulating half-life of Exenatide is ~2.4 h (immediate-release).

Is Exenatide the same as Byetta or Bydureon?

Byetta, and Bydureon are brand names of Exenatide — the same molecule in different approved presentations. This page is the molecule reference, not a prescribing guide.

Exenatide

A GLP-1 receptor agonist derived from Gila monster venom (exendin-4).

Also known as Byetta, Bydureon.

AnalogEstablishedBased on Glucagon-like peptide-1Compare with GLP-1 Compare lineage

A lizard's venom turned out to hold a durable copy of a human sentence. The class began as a loan from another species.

Identity

Class: GLP-1 receptor agonist (exendin-4, 39 aa)
Source: Synthetic exendin-4; originally from Gila monster venom
Receptor: GLP-1 receptor (GLP-1R)

Key properties

Evidence floorClinicalREF1CLIN1

Molecular weight

~4,186.6 Da

REF

Half-life (native)

~2.4 h (immediate-release)

CLIN

Model dosing

Approximate values for the native hormone; engineered analogs are often deliberately larger and far longer-acting. Each figure carries its own provenance tier, and the floor is the weakest of them - the Standard.

Mechanism

Exenatide is the synthetic form of exendin-4, a peptide from Gila monster venom that fully activates GLP-1R but — unlike human GLP-1 — is naturally resistant to DPP-4. That built-in resistance gives a far longer half-life than native GLP-1 without any acylation.

Same receptor, different fate at the enzyme. DPP-4 severs native GLP-1 in minutes; the Gila monster’s exendin-4 slips through uncut — the natural durability the whole weekly-injection class was reverse-engineered from.

In depth

The entire long-acting GLP-1 class begins with a lizard. The Gila monster eats a few times a year and somehow keeps its blood sugar stable through months of fasting; in its venom, John Eng found exendin-4, a peptide that fully activates the human GLP-1 receptor but shares only about half its sequence with human GLP-1. That divergence turns out to be the point — the lizard peptide is shaped so that DPP-4, the enzyme that erases human GLP-1 in two minutes, cannot cut it. Nature had already solved the durability problem; the drug industry just had to copy the answer.

Exenatide is that copy. As Byetta, a twice-daily injection, it became the first GLP-1 receptor agonist approved, in 2005 — proof that incretin biology could be a medicine, not just a physiology lecture. A microsphere formulation (Bydureon) later stretched it to once weekly, the same durability ladder the rest of the class would climb. For a few years the lizard peptide defined what an incretin drug was.

Its legacy is double. Scientifically, exendin-4 taught the field that a GLP-1 agonist did not have to look like GLP-1 — the pharmacophore could come from a different evolutionary branch and still work. Commercially, exenatide was the pioneer the weekly analogs displaced: semaglutide's acylation-and-albumin strategy bought a longer half-life with a human-like sequence, and the lizard retreated to a historical footnote. But every weekly incretin injection since is, in a sense, standing on scales.

Reference notes

Exendin-4's natural DPP-4 resistance is the discovery that made long-acting GLP-1 therapy feasible.
Shares only ~53% identity with human GLP-1 yet fully activates the receptor.
Available in immediate-release and extended-release (microsphere) formulations.

Common questions

What is Exenatide?: A GLP-1 receptor agonist derived from Gila monster venom (exendin-4). Structurally it is GLP-1 receptor agonist (exendin-4, 39 aa).
How does Exenatide work?: Exenatide is the synthetic form of exendin-4, a peptide from Gila monster venom that fully activates GLP-1R but — unlike human GLP-1 — is naturally resistant to DPP-4. That built-in resistance gives a far longer half-life than native GLP-1 without any acylation.
How strong is the evidence for Exenatide?: PeptideHormone grades Exenatide at the "Established" evidence tier — its mechanism and core effects are settled across the peer-reviewed literature. It is catalogued as an engineered analog built on an endogenous hormone, and the tier is an editorial judgment about the public literature that can change as the science does.
What is the half-life of Exenatide?: The reported circulating half-life of Exenatide is ~2.4 h (immediate-release).
Is Exenatide the same as Byetta or Bydureon?: Byetta, and Bydureon are brand names of Exenatide — the same molecule in different approved presentations. This page is the molecule reference, not a prescribing guide.

Selected literature

Curated peer-reviewed reviews, sourced from PubMed. Selected for relevance, not exhaustive — open any entry on PubMed for the full record and its primary citations.

1.GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art · Molecular metabolism, 2021 · PMID 33068776
2.Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials · International journal of molecular sciences, 2023 · PMID 37445623

External references

Exenatide in the public knowledge graph — the same entity resolved across the authoritative chemistry and protein databases.